1.Hidron, AI, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infection Control and Hospital Epidemiology 2008; 29: 996–1011.
2.Klevens, RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Journal of the American Medical Association 2007; 298: 1763–1771.
3.Cosgrove, SE, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infection Control and Hospital Epidemiology 2005; 26: 166–174.
4.Centers for Diseases Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin – United States, 1997. Morbidity and Mortality Weekly Report 1997; 46: 765–766.
5.Steinkraus, G, White, R, Friedrich, L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. Journal of Antimicrobial Chemotherapy 2007; 60: 788–794.
6.Wang, G, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. Journal of Clinical Microbiology 2006; 44: 3883–3886.
7.Hawser, SP, et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009. International Journal of Antimicrobial Agents 2011; 37: 219–224.
9.Clinical and Laboratory Standards Institute. Methods for dilutional antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Wayne, PA: CLSI, 2007.
10.Hidayat, LK, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Archives of Internal Medicine 2006; 166: 2138–2144.
11.Sakoulas, G, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Journal of Clinical Microbiology 2004; 42: 2398–2402.
12.Moise, PA, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrobial Agents and Chemotherapy 2007; 51: 2582–2586.
13.Moise-Broder, PA, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clinical Infectious Diseases 2004; 38: 1700–1705.
14.Soriano, A, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clinical Infectious Diseases 2008; 46: 193–200.
15.Lodise, TP, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrobial Agents and Chemotherapy 2008; 52: 3315–3320.
16.Wang, JL, et al. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: Mortality analyses and the impact of vancomycin, MIC = 2 mg/l, by the broth microdilution method. BMC Infectious Diseases 2010; 10: 159.
18.Yoon, YK, et al. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. Journal of Antimicrobial Chemotherapy 2010; 65: 1015–1018.
19.Kullar, R, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clinical Infectious Diseases 2011; 52: 975–981.
20.Holmes, NE, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. Journal of Infectious Diseases 2011; 204: 340–347.
21.Price, J, et al. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clinical Infectious Diseases 2009; 48: 997–998.
22.Lubin, AS, et al. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clinical Infectious Diseases 2011; 52: 997–1002.
23.Hsu, DI, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. International Journal of Antimicrobial Agents 2008; 32: 78–85.
24.Sader, HS, Rhomberg, PR, Jones, RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2009; 53: 3162–3165.
25.Vaudaux, P, et al. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2010; 54: 3861–3870.
26.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S18. Wayne, PA, CLSI, 2008.
27.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A9. Wayne, PA, CLSI, 2006.
28.Barton, TD, et al. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infection Control and Hospital Epidemiology 2005; 26: 93–99.
29.Gasink, LB, et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. American Journal of Medicine 2006; 119: e19–e25.
30.Lee, I, et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Archives of Internal Medicine 2009; 169: 379–383.
31.Quan, H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005; 43: 1130–1139.
32.Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. American Journal of Epidemiology 1989; 129: 125–137.
33.Hosmer, DW, Lemeshow, S. Applied Logistic Regression. New York, NY: John Wiley & Sons, 1989.
34.Harrell, FE Jr., Lee, KL, Mark, DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistical Medicine 1996; 15: 361–387.
35.Efron, B, Tibshirani, RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall, 1998.
36.Steyerberg, EW, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. Journal of Clinical Epidemiology 2001; 54: 774–781.
37.Anthony, K, et al. Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia. Infection Control and Hospital Epidemiology 2012; 33: 160–166.
38.Moore, CL, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clinical Infectious Diseases 2012; 54: 51–58.
39.Lodise, TP, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clinical Infectious Diseases 2003; 36: 1418–1423.
40.Paul, M, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy 2010; 65: 2658–2665.
41.Ender, M, et al. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2004; 48: 2295–2297.
42.Harrell, FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer, 2001.